drugset / Trial / NCT01342237
Tandem High Dose Chemotherapy and Autologous Stem Cell Rescue for High Risk Pediatric Brain Tumors
NaSingle-groupOpen-labelTreatment
Summary
The investigators plan to improve event free survival rate and reduce treatment related toxicities of pediatric patients with high risk/recurrent CNS tumors by administrating tandem high dose chemotherapy and autologous stem cell rescue.
Timeline
- Start
- 2011-03
- Primary completion
- 2014-02
- Completion
- 2014-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 350 mg/m2 | Intravenous |
| Subject | Carboplatin | Small molecule | 500 mg/m2 | Intravenous |
| Subject | Etoposide | Small molecule | 200 mg/m2 | Intravenous |
| Subject | Melphalan | Small molecule | 70 mg/m2 | Intravenous |
| Subject | Melphalan | Small molecule | 140 mg/m2 | Intravenous |
| Subject | Thiotepa | Other / unclassified | 300 mg/m2 | Intravenous |
| Subject | Topotecan | Small molecule | 2 mg/m2 | Intravenous |